Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells

Carmelo Carlo-Stella, Silvia L. Locatelli, Arianna Giacomini, Loredana Cleris, Elena Saba, Marco Righi, Anna Guidetti, Alessandro M. Gianni

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines. In vitro, sorafenib significantly decreased cell proliferation and phosphorylation levels of MAPK and PI3K/Akt pathways while increased apoptotic cell death. In vivo, sorafenib treatment resulted in a cytostatic rather than cytotoxic effect on tumor cell growth associated with a limited inhibition of tumor volumes. However, sorafenib induced an average 50% reduction of tumor vessel density and a 2-fold increase of necrotic areas. Upon sorafenib treatment, endothelial and tumor cells from SU-DHL-4V, Granta-519, and KMS-11 nodules showed a potent inhibition of either phospho-ERK or phospho-AKT, whereas a concomitant inhibition of phospho-ERK and phospho-AKT was only observed in HD-MyZ nodules. In conclusion, sorafenib affects the growth of lymphoid cell lines by triggering antiangiogenic mechanism(s) and directly targeting tumor cells.

Original languageEnglish
Article numbere61603
JournalPLoS One
Volume8
Issue number4
DOIs
Publication statusPublished - Apr 19 2013

Fingerprint

MAP Kinase Signaling System
lymphoma
Heterografts
blood vessels
Blood Vessels
Tumors
Lymphoma
cell lines
Cells
neoplasms
Neoplasms
phosphatidylinositol 3-kinase
cells
Cell Line
endothelial cells
cytotoxicity
cell death
cell growth
cell proliferation
phosphorylation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells. / Carlo-Stella, Carmelo; Locatelli, Silvia L.; Giacomini, Arianna; Cleris, Loredana; Saba, Elena; Righi, Marco; Guidetti, Anna; Gianni, Alessandro M.

In: PLoS One, Vol. 8, No. 4, e61603, 19.04.2013.

Research output: Contribution to journalArticle

Carlo-Stella, Carmelo ; Locatelli, Silvia L. ; Giacomini, Arianna ; Cleris, Loredana ; Saba, Elena ; Righi, Marco ; Guidetti, Anna ; Gianni, Alessandro M. / Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells. In: PLoS One. 2013 ; Vol. 8, No. 4.
@article{8ee803c620ac41c488fcc3a1e74e6862,
title = "Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells",
abstract = "The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines. In vitro, sorafenib significantly decreased cell proliferation and phosphorylation levels of MAPK and PI3K/Akt pathways while increased apoptotic cell death. In vivo, sorafenib treatment resulted in a cytostatic rather than cytotoxic effect on tumor cell growth associated with a limited inhibition of tumor volumes. However, sorafenib induced an average 50{\%} reduction of tumor vessel density and a 2-fold increase of necrotic areas. Upon sorafenib treatment, endothelial and tumor cells from SU-DHL-4V, Granta-519, and KMS-11 nodules showed a potent inhibition of either phospho-ERK or phospho-AKT, whereas a concomitant inhibition of phospho-ERK and phospho-AKT was only observed in HD-MyZ nodules. In conclusion, sorafenib affects the growth of lymphoid cell lines by triggering antiangiogenic mechanism(s) and directly targeting tumor cells.",
author = "Carmelo Carlo-Stella and Locatelli, {Silvia L.} and Arianna Giacomini and Loredana Cleris and Elena Saba and Marco Righi and Anna Guidetti and Gianni, {Alessandro M.}",
year = "2013",
month = "4",
day = "19",
doi = "10.1371/journal.pone.0061603",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells

AU - Carlo-Stella, Carmelo

AU - Locatelli, Silvia L.

AU - Giacomini, Arianna

AU - Cleris, Loredana

AU - Saba, Elena

AU - Righi, Marco

AU - Guidetti, Anna

AU - Gianni, Alessandro M.

PY - 2013/4/19

Y1 - 2013/4/19

N2 - The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines. In vitro, sorafenib significantly decreased cell proliferation and phosphorylation levels of MAPK and PI3K/Akt pathways while increased apoptotic cell death. In vivo, sorafenib treatment resulted in a cytostatic rather than cytotoxic effect on tumor cell growth associated with a limited inhibition of tumor volumes. However, sorafenib induced an average 50% reduction of tumor vessel density and a 2-fold increase of necrotic areas. Upon sorafenib treatment, endothelial and tumor cells from SU-DHL-4V, Granta-519, and KMS-11 nodules showed a potent inhibition of either phospho-ERK or phospho-AKT, whereas a concomitant inhibition of phospho-ERK and phospho-AKT was only observed in HD-MyZ nodules. In conclusion, sorafenib affects the growth of lymphoid cell lines by triggering antiangiogenic mechanism(s) and directly targeting tumor cells.

AB - The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines. In vitro, sorafenib significantly decreased cell proliferation and phosphorylation levels of MAPK and PI3K/Akt pathways while increased apoptotic cell death. In vivo, sorafenib treatment resulted in a cytostatic rather than cytotoxic effect on tumor cell growth associated with a limited inhibition of tumor volumes. However, sorafenib induced an average 50% reduction of tumor vessel density and a 2-fold increase of necrotic areas. Upon sorafenib treatment, endothelial and tumor cells from SU-DHL-4V, Granta-519, and KMS-11 nodules showed a potent inhibition of either phospho-ERK or phospho-AKT, whereas a concomitant inhibition of phospho-ERK and phospho-AKT was only observed in HD-MyZ nodules. In conclusion, sorafenib affects the growth of lymphoid cell lines by triggering antiangiogenic mechanism(s) and directly targeting tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=84876448099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876448099&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0061603

DO - 10.1371/journal.pone.0061603

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e61603

ER -